Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit

APMIS

Volumn 122, Issue 6, 2014, Pages 556-564

  Sun, Yu ^a   Liu, Jinwen ^a   Yang, Bo ^a   Sai, Xiaoyong ^a   Li, Tiande ^a   Wang, Dong ^b   Zhou, Rongbin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Atorvastatin; Endothelin 1 receptor agonist; MMP 9; NF B

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CATALASE; DARUSENTAN; ENDOTHELIN 1; GELATINASE B; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; EXPERIMENTAL ATHEROSCLEROSIS; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RABBIT MODEL; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; ATORVASTATIN; ENDOTHELIN-1 RECEPTOR AGONIST; MMP-9; NF-ΚB;

ANIMALS; AORTA, ABDOMINAL; ATHEROSCLEROSIS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ILIAC ARTERY; INFLAMMATION MEDIATORS; LIPIDS; MALE; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PHENYLPROPIONATES; PLAQUE, ATHEROSCLEROTIC; PYRIMIDINES; PYRROLES; RABBITS; RECEPTOR, ENDOTHELIN A; RNA, MESSENGER;

EID: 84901244713     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12185     Document Type: Article

References (35)

1. Hansson GK. Inflammation and immune response in atherosclerosis. Curr Atheroscler Rep 1999;1:150-5.
2. Hansson GK. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci 2001;947:157-65.
3. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90.
4. Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-46.
5. Henderson RD, Eliasziw M, Fox AJ, Rothwell PM, Barnett HJ. Angiographically defined collateral circulation and risk of stroke in patients with severe carotid artery stenosis. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Stroke 2000;31:128-32.
6. Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007;67(Suppl 1):17-27.
7. Liao JK. Statins: potent vascular anti-inflammatory agents. Int J Clin Pract Suppl 2004;143:41-8.
8. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16:624-9.
9. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F.
10. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.
11. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006;98:18P-25P.
12. Saijonmaa O, Nyman T, Fyhrquist F. Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages. Am J Physiol Heart Circ Physiol 2007;292:H1917-21.
13. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
14. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87:25C-32C.
15. Dusting GJ, Fennessy P, Yin ZL, Gurevich V. Nitric oxide in atherosclerosis: vascular protector or villain? Clin Exp Pharmacol Physiol Suppl 1998;25:S34-41.
16. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
17. Eglen RM, Michel AD, Sharif NA, Swank SR, Whiting RL. The pharmacological properties of the peptide, endothelin. Br J Pharmacol 1989;97:1297-307.
18. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995;146:819-26.
19. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992;189:994-1000.
20. Assender JW, Irenius E, Fredholm BB. Endothelin-1 causes a prolonged protein kinase C activation and acts as a co-mitogen in vascular smooth muscle cells. Acta Physiol Scand 1996;157:451-60.
21. Rizvi MA, Katwa L, Spadone DP, Myers PR. The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996;28:243-52.
22. Helset E, Sildnes T, Konopski ZS. Endothelin-1 stimulates monocytes in vitro to release chemotactic activity identified as interleukin-8 and monocyte chemotactic protein-1. Mediators Inflamm 1994;3:155-60.
23. Helset E, Ytrehus K, Tveita T, Kjaeve J, Jorgensen L. Endothelin-1 causes accumulation of leukocytes in the pulmonary circulation. Circ Shock 1994;44:201-9.
24. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
25. Jones GT, van Rij AM, Solomon C, Thomson IA, Packer SG. Endothelin-1 is increased overlying atherosclerotic plaques in human arteries. Atherosclerosis 1996;124:25-35.
26. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995;91:941-7.
27. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998;95:14367-72.
28. Narayanaswamy M, Wright KC, Kandarpa K. Animal models for atherosclerosis, restenosis, and endovascular graft research. J Vasc Interv Radiol 2000;11:5-17.
29. Kanazawa T, Tanaka M, Fukushi Y, Onodera K, Lee KT, Metoki H. Effects of low-density lipoprotein from normal rabbits on hypercholesterolemia and the development of atherosclerosis. Pathobiology 1991;59:85-91.
30. Hewistson TD, Wigg B, Becker GJ. Tissue preparation for histochemistry: fixation, embedding and antigen retrieval for light microscopy. Methods Mol Biol 2010;611:3-18.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta C(T)) Method. Methods 2011;25:402-8.
32. Wang N, Gibbons CH, Freeman R. Novel immunohistochemical techniques using discrete signal amplification systems for human cutaneous peripheral nerve fiber imaging. J Histochem Cytochem 2011;59:382-90.
33. Tanimoto A, Murata Y, Wang KY, Tsutsui M, Kohno K, Sasaguri Y. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem 2008;283:4643-51.
34. Yu Y, Koike T, Kitajima S, Liu E, Morimoto M, Shiomi M, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol 2008;23:1503-16.
35. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006;281:15099-109.